Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis

NCT00848055 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: AbGn168 intravenous infusion
DRUG: AbGn168 intravenous infusion
DRUG: AbGn168 intravenous infusion
DRUG: AbGn168 intravenous infusion
DRUG: AbGn168 intravenous infusion
DRUG: AbGn168 intravenous infusion
DRUG: AbGn168 intravenous infusion
DRUG: AbGn168 subcutaneous injection

Sponsor

Boehringer Ingelheim